RS54904B1 - Antibakterijske farmaceutske kompozicije - Google Patents

Antibakterijske farmaceutske kompozicije

Info

Publication number
RS54904B1
RS54904B1 RS20160458A RSP20160458A RS54904B1 RS 54904 B1 RS54904 B1 RS 54904B1 RS 20160458 A RS20160458 A RS 20160458A RS P20160458 A RSP20160458 A RS P20160458A RS 54904 B1 RS54904 B1 RS 54904B1
Authority
RS
Serbia
Prior art keywords
pharmaceutical compositions
antibacterial pharmaceutical
pharmaceutically acceptable
antibacterial
bibenzo
Prior art date
Application number
RS20160458A
Other languages
English (en)
Inventor
Francis Xavier Wilson
Peter David Johnson
Richard Vickers
Richard Storer
Graham Michael Wynne
Alan Geoffrey Roach
Moor Olivier De
Colin Richard Dorgan
Paul James Davis
Original Assignee
Summit Therapeutics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Therapeutics Plc filed Critical Summit Therapeutics Plc
Publication of RS54904B1 publication Critical patent/RS54904B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmaceutska kompozicija koja sadrži jedinjenje 2,2'-di(piridin-4-ul)-1H, 1'H-5,5'-bibenzo[d]imidazol, ili njegov farmaceutski prihvatljivi N-oksid, so, hidrat ili solvat, i farmaceutski prihvatljivi ekscipijens.Prijava sadrži još 5 patentnih zahteva.
RS20160458A 2008-12-02 2009-12-01 Antibakterijske farmaceutske kompozicije RS54904B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
EP14197877.5A EP2907813B1 (en) 2008-12-02 2009-12-01 Antibacterial pharmaceutical compositions

Publications (1)

Publication Number Publication Date
RS54904B1 true RS54904B1 (sr) 2016-10-31

Family

ID=40262471

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160458A RS54904B1 (sr) 2008-12-02 2009-12-01 Antibakterijske farmaceutske kompozicije

Country Status (28)

Country Link
US (3) US8975416B2 (sr)
EP (3) EP3095783A1 (sr)
JP (3) JP5665756B2 (sr)
KR (1) KR101643435B1 (sr)
CN (1) CN102227411B (sr)
AU (1) AU2009323854B2 (sr)
BR (2) BRPI0922220B8 (sr)
CA (1) CA2744962C (sr)
CY (2) CY1116383T1 (sr)
DK (2) DK2373631T3 (sr)
ES (2) ES2575908T3 (sr)
GB (1) GB0821913D0 (sr)
HK (2) HK1162169A1 (sr)
HR (2) HRP20150518T1 (sr)
HU (1) HUE029151T2 (sr)
IL (1) IL213325A (sr)
LT (1) LT2907813T (sr)
MX (1) MX2011005837A (sr)
NZ (1) NZ593111A (sr)
PL (2) PL2373631T3 (sr)
PT (2) PT2373631E (sr)
RS (1) RS54904B1 (sr)
RU (1) RU2525915C2 (sr)
SG (1) SG171939A1 (sr)
SI (2) SI2373631T1 (sr)
SM (2) SMT201500117B (sr)
WO (1) WO2010063996A2 (sr)
ZA (1) ZA201103751B (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151621A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
JP6506173B2 (ja) 2012-11-23 2019-04-24 セレス セラピューティクス インコーポレイテッド 相乗的細菌組成物並びにその生成及び使用の方法
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
BR112015018625A2 (pt) 2013-02-04 2017-09-19 Seres Therapeutics Inc composições e métodos
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
EP3074027A1 (en) 2013-11-25 2016-10-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
AU2018318132A1 (en) 2017-08-14 2020-02-27 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
EP3692030B1 (en) * 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts
WO2021009514A1 (en) 2019-07-17 2021-01-21 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
AR120680A1 (es) 2019-12-06 2022-03-09 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
AU2022283200A1 (en) * 2021-05-24 2023-11-23 Aimmax Therapeutics, Inc. Pristinamycin ia and flopristin combinations in treating or preventing bacterial infections
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
IL309232A (en) 2021-06-14 2024-02-01 Scorpion Therapeutics Inc History of urea which can be used to treat cancer
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (sr) * 1974-04-30 1975-11-11
JPS50154250A (sr) * 1974-05-31 1975-12-12
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
EP0793654A1 (de) * 1994-11-17 1997-09-10 F. Hoffmann-La Roche Ag Antibakterielle dibenzimidazol-derivate
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
EP1337520B1 (en) 2000-11-27 2004-12-15 Ciba SC Holding AG Substituted 5-aryl and 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazole derivatives as uv absorbers
HUP0303494A3 (en) 2000-12-15 2009-08-28 Vertex Pharma Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
FR2819180B1 (fr) * 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2002334217B2 (en) 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
KR101052433B1 (ko) 2002-06-13 2011-07-29 버텍스 파마슈티칼스 인코포레이티드 자이라제 및/또는 토포이소머라제 ⅳ 억제제로서의 2-우레이도-6-헤테로아릴-3ｈ-벤조이미다졸-4-카복실산 유도체 및 이를 포함하는 세균 감염 치료용 약제학적 조성물
US20050260126A1 (en) * 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
CA2504448C (en) 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2562763A1 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
ATE482213T1 (de) 2004-11-04 2010-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
JP2008527032A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なチエノピロール
EP1945209B1 (en) 2005-08-12 2018-05-30 United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
AU2007291190A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
JP2010513263A (ja) 2006-12-15 2010-04-30 ファイザー・プロダクツ・インク ベンズイミダゾール誘導体
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
JP5615902B2 (ja) 2009-04-02 2014-10-29 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ）Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ Ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ（Ｃｎｉｏ） イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
ES2632220T3 (es) 2009-06-15 2017-09-11 Rigel Pharmaceuticals, Inc. Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK)
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
WO2011151621A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease

Also Published As

Publication number Publication date
US20150150861A1 (en) 2015-06-04
HRP20150518T1 (hr) 2015-07-17
SI2373631T1 (sl) 2015-08-31
HK1162169A1 (en) 2012-08-24
US20120020950A1 (en) 2012-01-26
BRPI0922220B1 (pt) 2021-03-09
CA2744962A1 (en) 2010-06-10
SG171939A1 (en) 2011-07-28
DK2907813T3 (en) 2016-07-25
WO2010063996A2 (en) 2010-06-10
PT2373631E (pt) 2015-06-09
AU2009323854A2 (en) 2011-06-30
EP2907813B1 (en) 2016-04-27
US20160184283A1 (en) 2016-06-30
KR101643435B1 (ko) 2016-07-27
KR20110093925A (ko) 2011-08-18
BR122020013025B1 (pt) 2021-05-18
DK2373631T3 (en) 2015-05-26
PT2907813T (pt) 2016-08-05
HK1208668A1 (zh) 2016-03-11
WO2010063996A3 (en) 2010-12-29
PL2373631T3 (pl) 2015-10-30
LT2907813T (lt) 2016-10-10
BRPI0922220A2 (pt) 2015-12-29
AU2009323854A1 (en) 2010-06-10
ZA201103751B (en) 2014-10-29
NZ593111A (en) 2013-05-31
HRP20160597T1 (hr) 2016-09-23
CY1116383T1 (el) 2017-02-08
AU2009323854B2 (en) 2014-06-26
CN102227411B (zh) 2015-10-14
BRPI0922220A8 (pt) 2018-04-03
SMT201600259B (it) 2016-08-31
JP5665756B2 (ja) 2015-02-04
CN102227411A (zh) 2011-10-26
SMT201500117B (it) 2015-07-09
IL213325A0 (en) 2011-07-31
EP2373631A2 (en) 2011-10-12
HUE029151T2 (hu) 2017-02-28
MX2011005837A (es) 2011-11-18
JP2015078220A (ja) 2015-04-23
BRPI0922220B8 (pt) 2021-05-25
CA2744962C (en) 2017-06-06
US9314456B2 (en) 2016-04-19
EP2907813A1 (en) 2015-08-19
US9763925B2 (en) 2017-09-19
ES2575908T3 (es) 2016-07-04
JP2012510458A (ja) 2012-05-10
PL2907813T3 (pl) 2016-09-30
GB0821913D0 (en) 2009-01-07
RU2525915C2 (ru) 2014-08-20
RU2011127165A (ru) 2013-01-10
CY1117934T1 (el) 2017-05-17
EP3095783A1 (en) 2016-11-23
US8975416B2 (en) 2015-03-10
ES2537059T3 (es) 2015-06-02
JP2017048217A (ja) 2017-03-09
SI2907813T1 (sl) 2016-09-30
EP2373631B1 (en) 2015-02-25
IL213325A (en) 2016-02-29

Similar Documents

Publication Publication Date Title
RS54904B1 (sr) Antibakterijske farmaceutske kompozicije
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
UA94901C2 (ru) Антибактериальные производные пиперидина
ZA200807274B (en) Novel pyridine derivatives
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
IL192298A (en) Heterocyclic Compounds, Their Acceptable Salts, Pharmaceuticals Containing and Using Them
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
MY154909A (en) Novel thiophene derivatives
WO2006092599A3 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
UA101313C2 (uk) Щотижневе введення інгібіторів дипептидилпептидази
UA90742C2 (en) Pyrazolone derivatives
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
WO2006087544A8 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2011005052A3 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same